NeurologyLive

Is it December 1st already? Recap November with us with this month's edition of #TheAxon!

In a new update to the phase 3 RESILIENT-SMA study, treatment with investigational taldefgromab alfa (Biohaven) did not meet its primary end point in patients with spinal muscular atrophy (SMA); however, it did show signals of efficacy in biomarker-defined subgroups. Based on its effect on myostatin reduction and body composition, the company intends to accelerate the drug into a placebo-controlled phase 2 study of patients with obesity using a user-friendly, self-administered autoinjector. Read more: https://lnkd.in/exgaeYEz

Watch the on-demand presentation, “Managing SMA Across a Range of Patient Types: An Expert Forum” to understand the importance of early intervention in spinal muscular atrophy (SMA), and to learn about treatment goals and expectations across SMA patient types from our panel of experts. https://bit.ly/4b0x6IY

In our latest NeuroVocies, Rebecca M. Edelmayer, PhD, of Alzheimer's Association®, dived deeper into the role of blood biomarker tests for evolving #Alzheimer disease diagnosis and treatment over the next few years. #CTAD24 CTAD Clinical Trials on Alzheimer's Disease https://lnkd.in/eEvC86gd

New results from the phase 3 ENCORE trial revealed that treatment with AXS-12, an investigational agent for #narcolepsy, achieved its primary end point in reducing the number of #cataplexy attacks compared with placebo. Axsome Therapeutics, Inc. https://lnkd.in/eQUBQw2r

A newly published study showed that pediatric patients from Black and low-income backgrounds with #NMOSD experience significantly worse health outcomes compared with their nonHispanic White and more affluent peers. Nationwide Children's Hospital SRNA | connect. care. cure. ™ The Sumaira Foundation https://lnkd.in/eA8zA-8B

New podcast alert: Dr. Andy Berkowski discusses the 2024 American Academy of Sleep Medicine guidelines for RLS: shifting away from dopaminergic agents, prioritizing iron & alpha-2-delta ligands, and how these updates transform patient care. Listen in for insights on RLS treatment & prevention. #SleepMedicine #RLS #Neurology https://lnkd.in/e5tcxZTW

New findings from the phase 3 ENCORE trial revealed that treatment with AXS-12 (Axsome Therapeutics, Inc.), an investigational agent for narcolepsy, achieved its primary end point in reducing the number of cataplexy attacks compared with placebo. Coupled with other benefits in excessive daytime sleepiness, cognition, and work productivity, Axsome plans to move towards a new drug application filing for AXS-12 and intends to request a pre-NDA meeting with the FDA. https://lnkd.in/eQUBQw2r

In a new update, investigational HL192, an agent in development for #Parkinsons disease, met its primary end point of safety and tolerability in its first-in-human phase 1 study. HanAll Biopharma Daewoong Pharmaceutical https://lnkd.in/eSS4xrCv

New topline data from a phase 3 study showed that treatment with investigational simufilam did not meet each of its pre-specified co-primary, secondary, and exploratory biomarker end points in patients with mild-to-moderate #Alzheimers. https://lnkd.in/eyrbXueu